Short answer
OPKO HEALTH, INC. (OPK) filed its Q1 2026 10-Q quarterly report on Apr 28, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $124M (down 17.2% year over year) with net income of −$55M.
Q1 2026 key financials · XBRL
- Revenue
- $124M
- −17.2% YoY
- Net income
- −$55M
- +18.9% YoY
- Operating margin
- -41.1%
- Gross margin
- 36.8%
- EPS (diluted)
- −$0.07
- +30.0% YoY
Source: XBRL data from the OPKO HEALTH, INC. (OPK) Q1 2026 10-Q on SEC EDGAR. USD.
OPKO HEALTH, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes from the Form 10-K
- Liquidity risk: $447.999 million contractual obligations, including $246.643 million due thereafter under 2044 Royalty Financing
- Regulatory and legal risk: Funding needs depend on regulatory approvals, government investigations, payor claims, and ITA litigation outcomes
- Operational risk: Cash requirements depend on Somatrogon approval success, Rayaldee sales, and partners’ Mazdutide launch
- Currency risk: 32.7% of quarterly revenue denominated in non-USD currencies, primarily Chilean Peso and Euro
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OPKO HEALTH, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.